Cargando…

Antibody-Based Therapies in Multiple Myeloma

The unmet need for improved multiple myeloma (MM) therapy has stimulated clinical development of monoclonal antibodies (mAbs) targeting either MM cells or cells of the bone marrow (BM) microenvironment. In contrast to small-molecule inhibitors, therapeutic mAbs present the potential to specifically...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tai, Yu-Tzu, Anderson, Kenneth C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2011
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3200112/ https://www.ncbi.nlm.nih.gov/pubmed/22046572 http://dx.doi.org/10.1155/2011/924058

Ejemplares similares

Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma
por: Cho, Shih-Feng, et al.
Publicado: (2017)

Immunotherapeutic and Targeted Approaches in Multiple Myeloma
por: Nadeem, Omar, et al.
Publicado: (2020)

Bispecific antibodies in multiple myeloma treatment: A journey in progress
por: Cho, Shih-Feng, et al.
Publicado: (2022)

BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma
por: Cho, Shih-Feng, et al.
Publicado: (2020)

Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple Myeloma
por: Cho, Shih-Feng, et al.
Publicado: (2021)

Targeting the UPS as therapy in multiple myeloma
por: Chauhan, Dharminder, et al.
Publicado: (2008)

Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor
por: Joseph, Nisha S, et al.
Publicado: (2021)

Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy
por: Cho, Shih-Feng, et al.
Publicado: (2018)

Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1
por: Tai, Yu-Tzu, et al.
Publicado: (2018)

Bruton's tyrosine kinase: oncotarget in myeloma
por: Tai, Yu-Tzu, et al.
Publicado: (2012)

Identification of novel myeloma-specific XBP1 peptides able to generate cytotoxic T lymphocytes: A potential therapeutic application in multiple myeloma
por: Bae, Jooeun, et al.
Publicado: (2011)

Identification and validation of ecto-5' nucleotidase as an immunotherapeutic target in multiple myeloma
por: Ray, Arghya, et al.
Publicado: (2022)

The Anti-CD38 Antibody Therapy in Multiple Myeloma
por: Petrucci, Maria Teresa, et al.
Publicado: (2019)

Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy
por: Richardson, Paul, et al.
Publicado: (2010)

Multiple myeloma: the (r)evolution of current therapy and a glance into the future
por: Gulla', Annamaria, et al.
Publicado: (2020)

Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma
por: Radocha, Jakub, et al.
Publicado: (2021)

Emerging Role of Antibody-Drug Conjugates and Bispecific Antibodies for the Treatment of Multiple Myeloma
por: Tai, Waqqas, et al.
Publicado: (2022)

Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma
por: Adamia, Sophia, et al.
Publicado: (2022)

HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications
por: Harada, Takeshi, et al.
Publicado: (2017)

New Frontiers in the Treatment of Multiple Myeloma
por: Hwang, Janice Jin, et al.
Publicado: (2006)

Antibody-drug conjugate therapies in multiple myeloma—what’s next on the horizon?
por: Hartley-Brown, Monique, et al.
Publicado: (2022)

Targeting BCMA in Multiple Myeloma: Advances in Antibody-Drug Conjugate Therapy
por: Xing, Lijie, et al.
Publicado: (2023)

γ-secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiation
por: Chen, Hailin, et al.
Publicado: (2022)

BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
por: Kurata, Keiji, et al.
Publicado: (2023)

Resistance Mechanisms towards CD38−Directed Antibody Therapy in Multiple Myeloma
por: Franssen, Laurens E., et al.
Publicado: (2020)

KDM6B modulates MAPK pathway mediating multiple myeloma cell growth and survival
por: Ohguchi, Hiroto, et al.
Publicado: (2017)

The Role of Monoclonal Antibodies in the Era of Bi-Specifics Antibodies and CAR T Cell Therapy in Multiple Myeloma
por: Mohan, Meera, et al.
Publicado: (2021)

Bortezomib in the management of multiple myeloma
por: Laubach, Jacob P, et al.
Publicado: (2009)

Immune-based therapies in the management of multiple myeloma
por: Zanwar, Saurabh, et al.
Publicado: (2020)

Monoclonal Antibodies for the Treatment of Multiple Myeloma: An Update
por: Abramson, Hanley N.
Publicado: (2018)

Bispecific antibodies for non-Hodgkin’s lymphomas and multiple myeloma
por: Castaneda-Puglianini, Omar, et al.
Publicado: (2021)

Author Correction: Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma
por: Adamia, Sophia, et al.
Publicado: (2022)

Monoclonal Antibody Therapies in Multiple Myeloma: A Challenge to Develop Novel Targets
por: Nishida, Hiroko, et al.
Publicado: (2019)

Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond
por: Chim, C S, et al.
Publicado: (2018)

New therapies in multiple myeloma
por: Merchionne, F., et al.
Publicado: (2007)

Diagnosis and therapy of multiple myeloma
por: Palumbo, Antonio, et al.
Publicado: (2013)

Targeted Therapies for Multiple Myeloma
por: Leow, Christopher Chang-Yew, et al.
Publicado: (2021)

Targeted therapy of multiple myeloma
por: Zhou, Shan, et al.
Publicado: (2021)

Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma
por: Samur, Mehmet Kemal, et al.
Publicado: (2021)

The biological significance of histone modifiers in multiple myeloma: clinical applications
por: Ohguchi, Hiroto, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_gm53vgrad2n64gohl28ecu2rqq